Aosaikang (002755): Initial Signs of Successful Innovation-Driven Transformation Emerge, Marking a Turning Point in Performance

Event Description: In April 2026, Aosaikang released its 2025 annual report: for the full year of 2025, the company achieved revenue of RMB 1.779 billion (up 0.08% year-over-year) and net profit attributable to shareholders of RMB 237 million (up

长江证券Jun 1 07:32

Express News | Innovative drug stocks staged a strong rally, with Aosaikang hitting the daily limit up.

BreakingsMay 20 09:36

Orient Securities: The pharmaceuticals and biotechnology industry is expanding overseas, presenting an excellent opportunity to capitalize on contract manufacturing for innovative drugs.

Domestic centralized procurement and healthcare reform policies are gradually becoming more moderate, while international operations, after years of cultivation, have already gained momentum and continue to accelerate overseas expansion.

Zhitong FinanceMay 6 09:16

Aosaikang (002755) 2025 Annual Report and Q1 Earnings Commentary: Liotinib Approval Included in National Reimbursement Drug List; Sales Growth Expected

Report Summary: Aosaikang has entered the first year of commercialization of innovative drugs, with Liotinib tablets approved for marketing. Multiple innovative drug pipelines are currently under clinical development. We assign an 'Overweight' rating. Key investment highlights: We assign an 'Overweight' rating. We forecast 2026-

Guotai Haitong SecuritiesMay 1 00:00

Aosaikang: First Quarter Report for 2026

SZSIApr 29 00:00 · Announcements

Aosaikang: 2025 Annual Report

SZSIApr 29 00:00 · Announcements